Effectiveness of Guanxinning Tablet on the Stable Coronary Artery Disease based on the Real World: A Multi-center Registration Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900027448

Enrollment

Unknown

Registered

2019-11-13

Start date

2019-12-01

Completion date

Unknown

Last updated

2019-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stable Coronary Heart Disease

Interventions

Guanxinning tablet group:taken Guanxinning tablets

Non-Guanxinning tablet group:Non- taken Guanxinning tablets

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with stable coronary artery disease with definitive diagnosis (2) Voluntary participation in this research

Exclusion criteria

Exclusion criteria: Other conditions considered unsuitable for participation in this research by the researchers.

Design outcomes

Primary

Measure	Time frame
Major Adverse Cardiovascular and Cerebrovascular Events (All-cause death, cardiovascular death, non-fatal myocardial infarction, stent thrombosis, target lesion revascularization and cerebral arterial thrombosis);	—

Secondary

Measure	Time frame
Re-hospitalization for unstable angina;cardiac insufficiency;arrhythmia;TCM main symptom score;Seattle Angina Questionnaire;	—

Countries

China

Contacts

Public ContactGao rui

Xiyuan Hospital, CACMS

ruigao@126.com+86 010-62835653

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026